Revenue: EUR307 million, up by 4.3% in organic growth. EBITDA: EUR45 million, compared with a loss of EUR1 million last year. Net Income Group Share: EUR20 million profit for 2025. Financial Net Debt: ...

Zevra Therapeutics Inc (ZVRA) reports robust financial performance with significant contributions from MIPLYFFA, despite challenges in operating expenses and market variability.

Management is not providing 2026 annual guidance at this time. Albert explained, "We plan to come back to the market with our full year revenue and adjusted EBITDA guidance no later than our first ...